Literature DB >> 3928062

Reversal of liver damage due to long term methyltestosterone and safety of non-17 alpha-alkylated androgens.

C P Lowdell, I M Murray-Lyon.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928062      PMCID: PMC1417521          DOI: 10.1136/bmj.291.6496.637

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN: 0267-0623


× No keyword cloud information.
  4 in total

1.  [Anabolic steroids and cholestasis].

Authors:  V Nusinovici
Journal:  Med Chir Dig       Date:  1974

Review 2.  Hepatic lesions caused by anabolic and contraceptive steroids.

Authors:  K G Ishak
Journal:  Semin Liver Dis       Date:  1981-05       Impact factor: 6.115

3.  Hepatic lesions in patients on anabolic androgenic therapy.

Authors:  H Turani; J Levi; D Zevin; E Kessler
Journal:  Isr J Med Sci       Date:  1983-04

4.  Hyperplasia and prolapse of hepatocytes into hepatic veins during longterm methyltestosterone therapy: possible relationships of these changes to the developement of peliosis hepatis and liver tumours.

Authors:  F J Paradinas; T B Bull; D Westaby; I M Murray-Lyon
Journal:  Histopathology       Date:  1977-07       Impact factor: 5.087

  4 in total
  5 in total

1.  Pharmacokinetics of modified slow-release oral testosterone over 9 days in normal men with experimental hypogonadism.

Authors:  Ada Lee; Katya Rubinow; Richard V Clark; Ralph B Caricofe; Mark A Bush; Hui Zhi; Mara Y Roth; Stephanie T Page; William J Bremner; John K Amory
Journal:  J Androl       Date:  2011-08-25

2.  Pharmacokinetics of 2 novel formulations of modified-release oral testosterone alone and with finasteride in normal men with experimental hypogonadism.

Authors:  Christin N Snyder; Richard V Clark; Ralph B Caricofe; Mark A Bush; Mara Y Roth; Stephanie T Page; William J Bremner; John K Amory
Journal:  J Androl       Date:  2010-04-08

Review 3.  Recent developments in the toxicology of anabolic steroids.

Authors:  S Graham; M Kennedy
Journal:  Drug Saf       Date:  1990 Nov-Dec       Impact factor: 5.606

4.  Pharmacokinetics of a new testosterone transdermal delivery system, TDS-testosterone in healthy males.

Authors:  Z Chik; A Johnston; A T Tucker; S L Chew; L Michaels; C A S Alam
Journal:  Br J Clin Pharmacol       Date:  2006-03       Impact factor: 4.335

5.  A new oral testosterone (TLANDO) treatment regimen without dose titration requirement for male hypogonadism.

Authors:  Anthony DelConte; Kongnara Papangkorn; Kilyoung Kim; Benjamin J Bruno; Nachiappan Chidambaram; Mohit Khera; Irwin Goldstein; Tobias S Kohler; Martin Miner; Adrian S Dobs; Mahesh V Patel
Journal:  Andrology       Date:  2022-01-18       Impact factor: 4.456

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.